16-2084553-C-T
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP6BS2
The NM_000548.5(TSC2):c.4331C>T(p.Pro1444Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000373 in 1,609,080 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P1444A) has been classified as Likely benign.
Frequency
Consequence
NM_000548.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152222Hom.: 0 Cov.: 34
GnomAD3 exomes AF: 0.00000832 AC: 2AN: 240276Hom.: 0 AF XY: 0.0000152 AC XY: 2AN XY: 131780
GnomAD4 exome AF: 0.00000343 AC: 5AN: 1456740Hom.: 0 Cov.: 33 AF XY: 0.00000414 AC XY: 3AN XY: 724878
GnomAD4 genome AF: 0.00000656 AC: 1AN: 152340Hom.: 0 Cov.: 34 AF XY: 0.00 AC XY: 0AN XY: 74486
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 05, 2022 | The p.P1444L variant (also known as c.4331C>T), located in coding exon 33 of the TSC2 gene, results from a C to T substitution at nucleotide position 4331. The proline at codon 1444 is replaced by leucine, an amino acid with similar properties. This alteration was detected in a cohort of 2393 families with autism spectrum disorder who did not exhibit severe neurological defects (Saskin A et al. J Hum Genet, 2017 Jun;62:657-659). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Tuberous sclerosis 2 Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 04, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at